---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pathophysiology"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pathophysiology. Topics: Cellular and humoral immune mechanisms leading to macrophage-mediated demyelination, Complement activation pathways: the classical pathway is initiated through the C1 complex, Complement deposition in sural nerve biopsies, Systemic complement activation in serum and cerebrospinal fluid, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Cellular and humoral immune mechanisms leading to macrophage-mediated demyelination

> “The pathogenesis of CIDP involves a complex interplay of multiple aberrant immune responses, creating a pro-inflammatory environment, subsequently inflicting damage on the myelin sheath.”
> “Histopathological changes in CIDP include breakdown of the blood–nerve barrier (BNB), segmental demyelination near the nodes of Ranvier, interstitial edema, and endoneurial inflammatory cell infiltration, including lymphocytes and macrophages and varying degrees of admixed axonal damage”
> “The response to plasma exchange therapy indicates the important role of circulating factors in CIDP pathogenesis”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-2"></a>

### Complement activation pathways: the classical pathway is initiated through the C1 complex

> “Complement activation occurs through three different pathways: classical (C1q), lectin (mannose-binding lectins or ficolin), and alternative (C3 autoactivation or properdin), which converge at C3, the most abundant complement protein found in the blood”
> “Subsequently, the effector proteins C3a, C3b, and C5a and the membrane attack complex (MAC, C5b-9) are generated for target cell lysis”
> “The complement system appears to play a role in promoting macrophage-mediated demyelination.”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

> “Riliprubart, also known as SAR445088, targets active C1s protein, a C1 complex serine protease, responsible for activating the classical complement pathway.”

Source: [Stascheit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449320/)

<a id="topic-2.2.1.4-3"></a>

### Complement deposition in sural nerve biopsies

> “Overall, 94% (n = 52) revealed abnormal and prominent deposition of terminal complement complex C5b-9 on endoneurial capillaries.”
> “In contrast, there was no complement deposition in NDC nor DC.”

Source: [Stascheit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449320/)

> “C4d was deposited on the myelin sheaths in all patients with CIDP, with significantly higher density and intensity than in controls. C3c was detected in three of the nine patients with CIDP, while C5b-9 was not detected.”
> “The classical and/or lectin pathways are predominantly involved in CIDP pathogenesis.”

Source: [Murakami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456398/)

> “In an early study, sural nerve biopsy specimens from seven patients with chronic relapsing demyelinating polyneuropathy showed deposition of IgM in intraneural blood vessels in all patients and deposition of C3 in six of the seven patients.”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-4"></a>

### Systemic complement activation in serum and cerebrospinal fluid

> “Serum levels of activated complement proteins—C3a, C4a, Ba, Bb, C5a, and the soluble terminal complement complex sC5b-9 (sTCC)—were significantly elevated in CIDP patients compared to healthy donors (HD)”
> “Notably, concentrations of complement proteins indicative for more proximal activation of the classical and lectin (C1q, C4a, C4) pathway as well as of the alternative pathway (Ba, Bb) were also strikingly increased in CIDP compared to both CMT and HD”
> “Among CIDP patients, those with active, unstable disease exhibited significantly higher levels of terminal complement components (C5a and sTCC) compared to patients with stable disease or in remission”

Source: [Stascheit et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12794542/)

> “A study compared serum and CSF levels of C5a and terminal complement complex (TCC) in 21 newly diagnosed, treatment-naïve CIDP patients, with that of 29 control patients with noninflammatory neurological diseases. CIDP patients had significantly higher mean serum and CSF levels of C5a and TCC than control patients”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-5"></a>

### Classical pathway inhibition at C1s in a human cell-based model of demyelinating neuropathy

> “Patient autoantibody binding was sufficient to activate the classical complement pathway resulting in detection of C3b and C5b-9 deposits.”
> “TNT005 rescued the serum-induced complement deposition and functional deficits while treatment with an isotype control antibody had no rescue effect.”

Source: [Rumsey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540753/)

> “A human CIDP model was created by treatment of Schwann cell and motoneuron cultures with CIDP patient-derived serum, which triggered classical complement pathway activation and, subsequently, the deposition of C3b and C5b-9. Furthermore, treatment with a test monoclonal antibody inhibitor of C1s, TNT005, resulted in abrogation of complement deposition and rescued the electrophysiological deficits”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-6"></a>

### Complement-independent mechanisms in IgG4 paranodal antibody disease

> “It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing”
> “Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

> “The IgG4 antibodies exert pathogenic effects on their targeted antigens by blocking enzymatic activity or disrupting protein–protein interactions affecting signal transduction pathways, but not by activating complement, binding to inhibitory FcγRIIb receptor or engaging in cross-linking of the targeted antigen with immune complex formation as the IgG1-IgG3 antibody subclasses do.”

Source: [Dalakas (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294117/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
